Who are Medium Dose PF-07328948's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, oseltamivir and chinese medicinal herbs, Latanoprost plus adjunctive glaucoma medication.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medium-dose-pf-07328948.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Medium Dose PF-07328948 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medium Dose PF-07328948 (medium-dose-pf-07328948) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Unknown. Area: Infectious Disease.

marketed Unknown Unknown Infectious Disease Live · refreshed every 30 min

Target snapshot

Medium Dose PF-07328948 (medium-dose-pf-07328948) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Medium Dose PF-07328948 TARGET	medium-dose-pf-07328948	Pfizer	marketed	Unknown	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
oseltamivir and chinese medicinal herbs	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown
Latanoprost plus adjunctive glaucoma medication	Latanoprost plus adjunctive glaucoma medication	Sight Sciences, Inc.	marketed	Prostaglandin analog with adjunctive glaucoma agent	FP prostaglandin receptor (latanoprost component); adjunctive target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Unknown class)

Pfizer · 24 drugs in this class
· 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Bursa Yuksek Ihtisas Training and Research Hospital · 1 drug in this class
Dongkook Pharmaceutical Co., Ltd. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Gloucestershire Hospitals NHS Foundation Trust · 1 drug in this class
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Medium Dose PF-07328948 — Competitive Intelligence Brief. https://druglandscape.com/ci/medium-dose-pf-07328948. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing